Scynexis secured a new Biomedical Advanced Research and Development Authority (BARDA) contract worth $214 million to develop SCY-247 for invasive fungal infections. The agreement expands the company’s government-supported work aimed at improving treatment options for serious, drug-resistant fungal disease. BARDA funding typically emphasizes late-stage development readiness and potential public-health deployment, and it can reduce financing pressure while accelerating trial and product development milestones. For antifungal developers, the award signals continued federal prioritization of antifungal pipeline gaps and continued interest in platform-driven candidate maturation through government-industry collaboration.